Latest news with #HypertrophicCardiomyopathy
Health Line
3 days ago
- Health
- Health Line
How Does Hypertrophic Cardiomyopathy Look Inside the Body?
Hypertrophic cardiomyopathy (HCM) is a condition that thickens some of the heart's muscles, making it harder to pump blood. Hypertrophic cardiomyopathy (HCM) usually affects the ventricular septum, which is located between your right and left ventricles (the lower chambers of your heart). A thicker ventricular septum takes up more space and can affect blood flow, especially through the left ventricle. HCM is genetic, so if one person has the condition, others in the family should also get checked. Symptoms include fatigue, dizziness, shortness of breath, chest pain, or an irregular heart rate. Sometimes, there are no symptoms. HCM can be diagnosed with an echocardiogram, a test that shows an image of your heart. Other tests may also be needed. Over time, HCM can worsen, so managing the condition is important. Many people with HCM take medications to manage their symptoms, while some need surgeries or procedures to improve blood flow through the heart. Explore what a typical heart looks like versus what it looks like with HCM in the interactive experience below.
Yahoo
02-04-2025
- Business
- Yahoo
Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events'
Shares of Edgewise Therapeutics fell sharply Wednesday after the company released data for its latest clinical trial. The drug accomplished its main goal, but side effects reported by some patients raised concerns. Shares of Cytokinetics, one of Edgewise's competitors, surged in Therapeutics (EWTX) shares tumbled more than 20% Wednesday after the developmental drug company issued the results of its latest clinical trial. The company released the results of a Phase 2 trial for EDG-7500, a drug to treat Hypertrophic Cardiomyopathy (HCM), a condition that involves thickened heart muscles, which can make it more difficult for the heart to pump blood effectively. Edgewise said the drug largely accomplished its goal of reducing left ventricular outflow tract gradient (LVOT-G)--a metric that measures how difficult it is for the heart to pump blood--"without meaningful changes in left ventricular ejection fraction (LVEF)." However, the drug's side effects have overshadowed the positive results. The most common side effects were dizziness and an infection in the upper respiratory tract, along with atrial fibrillation (AF), also known as an irregular heartbeat. However, "two participants experienced serious adverse events of AF requiring cardioversion," or treatment to get a heart back to a normal rhythm. The company said that the rate of patients who experienced AF was within the range of similar studies with other drugs. According to Investor's Business Daily, RBC Capital Markets analyst Leonid Timashev wrote in a note, "The fact that two were serious is a complexity that could prompt the FDA to review this closely." Shares of Cytokinetics (CYTK), which is working on a competing drug, jumped 10% on the concerning results for Edgewise. Shares of Edgewise were down 21%. Read the original article on Investopedia Sign in to access your portfolio
